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Transcriptional regulation of the human c-myc gene
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Summary The involvement of c-myc in the genesis of animal neoplasia is now well documented for several
systems. In order to define the precise role played by the myc gene in tumorigenesis, a better understanding of
the normal regulation of myc expression is necessary. We have begun a study of the cis-acting regulatory
sequences within the 5' flanking domain of the human c-myc gene. Regions important for myc promoter
function have been identified by linkage to the coding sequences of the bacterial chloramphenicol
acetyltransferase (cat) gene. Promoter deletion studies and in vivo competition assays for c-myc/cat
recombinant plasmids have allowed the identification of a proximal 'core' promoter region capable of
directing high levels of CAT activity. Further upstream a negative regulatory element (NRE2) has been
identified which is capable of repressing cat gene expression and which functions by interaction with a trans-
acting factor(s). Preliminary data suggests detection of NRE2 is dependent on both the type and amount of
carrier DNA used in transient CAT assays. Initial experiments further indicate the involvement of at least two
other distal regulatory domains, a negative regulatory domain (NREI) and a putative enhancer-type region
(E). In vitro footprint analysis has allowed the identification of DNA binding proteins which interact with
NRE2 and the 'core' promoter. NRE2 contains binding sites for transcription factors Spl and CTF. The
'core' promoter domain appears to be highly complex and possesses several Spl binding sites.
The myc gene was first described as the oncogene of certain
highly transforming avian retroviruses (reviewed by Hayman,
1983). Since then a substantial body of evidence has
accumulated suggesting that the myc gene is intimately
associated with the control of cellular proliferation and
differentiation. Thus experimental and spontaneous tumours
in rodents and cats have been observed which contain
defective retroviruses expressing transduced v-myc genes
while a variety of avian, rodent and feline tumours express c-
myc genes activated by proviral DNA insertion (Hayward et
al., 1981; Corcoran et al., 1984; Neil et al., 1984). The c-myc
locus is also interrupted by translocation in human Burkitt's
lymphoma (BL) and murine plasmacytoma (MPC),
(reviewed by Marcu, 1987) and by amplification both in
some promyelocytic leukaemia cell lines and in some cases of
human breast cancer (reviewed by Alitalo, 1985).
Further evidence for effects of myc on growth are
provided by experiments which show that when the gene,
linked to strong transcriptional enhancers, is transfected into
cells in culture perturbations in differentiation patterns are
observed (Coppola & Cole, 1986). Similarly, the c-myc gene
is capable of inducing multiple neoplasms in transgenic mice
when fused to immunoglobulin enhancers (Adams et al.,
1985) or a mouse mammary tumour virus LTR (Leder et al.,
1986).
Unlike the ras gene family, mutations within the coding
sequences may not be an important feature in converting
myc from a proto-oncogene to an oncogene. Thus feline v-
myc coding sequences are virtually unaltered compared to
the feline c-myc (Stewart et al., 1986). The bulk of the
present evidence suggests that aberrant expression of c-myc
is the principal mechanism for oncogenic conversion.
The current view of the structure of the c-myc gene is
shown in Figure 1. Expression may be regulated under
,normal' circumstances at at least three levels. Firstly, there
is regulation at the level of initiation of transcription,
affected by cis-acting regulatory domains 5' to the two main
cap sites (P1 and P2) and perhaps by other domains within
the body of the gene (reviewed by Marcu, 1987). During
terminal differentiation of B cells, red cells and monocytes c-
myc expression is switched off, and in the case of HL60
promyelocytic cells this partly occurs as a result of reduced
initiation of transcription (Siebenlist et al., 1988). Secondly,
in quiescent murine fibroblasts, non-proliferating HL60 cells,
Correspondence: J.C. Lang.
Pvu II
-350
HI II KpnI AccI Rsal Pvull
-2319 -1052 -607 -290 PJ 4511
l llO~ifP2
I sII1 112 HI1l\\ \//1
MYC22
Figure 1 Structure of the human c-myc gene, exons 1-3 are
represented by an open box and the coding regions of proposed
c-myc proteins MYC 1 and MYC 2 (Hann et al., 1988) by a solid
box. Previously described in vivo hypersensitive sites 1-1112
(Siebenlist et al., 1984) are indicated. The position of relevant
restriction enzyme sites are shown relative to c-myc RNA cap
site P1.
and in human mononuclear cells (MNC) the absence of full
length c-myc transcripts is associated with an apparent block
in elongation of already initiated RNA, located at a point
close to the junction of exon 1 and the first intron (Bentley
& Groudine, 1986b; Eick & Bornkamm, 1986; Nepveu et al.,
1987). This block is overcome on mitogen stimulation of the
cell cycle (Eick et al., 1987; Nepveu et al., 1987). Thirdly, c-
myc RNA is known to have a short half life which is
apparently lengthened in some murine plasmacytomas and
during differentiation of F9 teratocarcinoma stem cells
(Piechaczyk et al., 1985; Dean et al., 1986).
It is not yet fully understood how the changes in the c-myc
locus observed in tumour cells affect regulation. The trans-
locations observed in BL and MPC often, but not always,
involve breakpoints within the transcriptional control region
of c-myc. This might disrupt normal regulatory sequences
(Yang et al., 1985). Alternatively, transcriptional regulatory
sequences within the immunoglobulin locus translocated to
the c-myc gene may exert a dominant effect on c-myc as may
retroviral LTRs found adjacent to c-myc in lymphomas of
chickens, mice and cats (Hayward et al., 1981; Payne et al.,
1984; Corcoran et al., 1984; Neil et al., 1984; O'Donnell et
al., 1985). In many cases of BL, however, aberrant myc
expression may be due to mutation of sequences located at
the 3' end of exon 1 thought to be involved in an elongation
block to transcription (Cesarman et al., 1987). Alternatively,
mutations located at this site might affect the expression of
the proposed MYC 1 protein (Hann et al., 1988). The
mechanisms of alteration in cases of amplification of c-myc,
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and in those cases where no rearrangement in the myc locus
is apparent, remain to be investigated.
It seems obvious that greater understanding of the normal
regulation of myc expression will be necessary for analysis of
the alterations which occur during oncogenic conversion. In
this paper we summarise our own studies of cis-acting
regulatory sequences within the 5' flanking domain of the
human c-myc gene. Such sequences were identified by
linkage to the bacterial chloramphenicol acetyltransferase
gene (cat), and in some cases further characterised by
analysis of DNA binding proteins using in vitro DNAase I
footprint analysis.
Identification of transcriptionally active domains within the
5' flanking sequence of c-myc
We linked the 5' flanking sequence and most of the first
exon sequence of c-myc (nucleotides -2319 to + 511, Figure
1) to the bacterial cat gene. This interrupts the myc
sequences at which an elongation block to transcription has
been suggested and also removes all known coding sequences
for MYC 1 and 2 (see Figure 1). The cat gene is then fused
to untranslated myc leader sequences and placed under
transcriptional control of the myc promoter. A series of 5'
terminal deletions and internal deletions were also
constructed. Following transfection into murine fibroblasts
(LATK-) and human epithelial cells (HeLa), relative levels
of CAT activity were measured using transient assays. In
other experiments, various domains of the 5' flanking
sequence were transferred to cat under control of heter-
ologous promoters and CAT activity similarly measured.
This approach permitted identification of cis-acting
regulatory domains affecting the expression of cat.
The results have been reported in detail elsewhere
(Whitelaw et al., 1988) but are summarised in Figure 2.
Evidence was obtained for a positive regulatory element,
perhaps an enhancer, located between -2319 and - 1980
relative to P1. From Figure 2 it can be seen that this domain
does not encompass in vivo DNAase hypersensitive site I.
Closer to the cap site, a cis-acting negative regulatory
element (NRE 1) encompassing hypersensitive site II1 was
identified, which mapped between - 1527 to - 1246.
Between - 1052 and -607 another strong negative element,
NRE2 encompasses hypersensitive site 112. Much closer to
the cap site a positive acting region was found which is in
the domain containing hypersensitive sites 1111 and III2, and
we presume this corresponds to the 'core' promoter.
Cis-acting negative regulatory sequences have also been
reported for the human and murine c-myc genes by others
(Chung et al., 1986; Remmers et al., 1986; Hay et al., 1986;
Lipp et al., 1987). Comparison of the results reported from
various laboratories suggests that the situation is complex.
Remmers et al. and Lipp et al. find negative regulatory
domains located between -1188 and -428 and - 1052 and
-511 respectively. These results are consistent with our own
which locate NRE2 to within a 445 bp sequence (- 1052 to
-607). In contrast, Chung et al. and Hay et al. describe
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Figure 2 A model for cis-acting transcriptional control domains
within the human c-myc regulatory region. Transcriptional
regulatory domains defined by in vivo CAT assays and in vitro
DNAse 1 footprint studies are indicated. Solid circle represents
Spl binding sites, open circle Spl-like binding site and solid oval
CTF binding sites. The TATAA boxes (T) are indicated.
negative elements between -607 to -407 and -353 to 293
respectively, outside the map location of NRE2. Chung et al.
(1986) also describe two additional negative regions located
in the first exon and the first intron, domains which we have
not yet examined. It is suggested that the latter element may
be involved in the elongation block proposed by Bentley and
Groudine (1986b).
It is clear that while various laboratories have detected
negative regulatory elements, their reported locations (and
the strength of their effects) appear to vary. The reasons for
this are not yet known but one factor may be the different
cell types and the different conditions used in the transient
assays which most laboratories utilise.
Preliminary experiments from our laboratory indicate that
one such variable may be the type and amount of carrier
DNA used. We measured transient CAT expression from
equimolar amounts of cat/myc recombinants containing the
entire myc 5' regulatory region or with a terminal deletion to
position -290, which removes hypersensitive sites I, II1, and
112 and also E, NRE1 and NRE2. Mouse embryo, salmon
sperm or pUC18 plasmid DNA was used as carrier in
varying amounts. The results are shown in Figure 3 and
reveal two important effects. Firstly, no significant difference
in CAT activity between the full length and deleted plasmids
is obtained at carrier DNA concentrations of less than lO,ug
per plate. Secondly, the deleted plasmid directs substantially
more CAT activity than the full length construction at
mouse embryo and salmon sperm carrier DNA
concentrations of between 10 and 60 pg per plate. In
contrast, using pUC18 DNA as carrier, no clear difference in
CAT levels between the full length and deleted plasmids was
observed at all carrier DNA concentrations measured.
However, these effects should not be confused with the
general decrease in CAT levels observed as the amount of
carrier DNA increases. This additional factor is probably
due to reduced efficiency of DNA transfection at higher
carrier DNA concentrations and can equally be observed
with recombinants containing the cat gene linked to other
non-myc promoter sequences (data not shown).
We tentatively propose the following explanation for these
effects. The 5' flanking sequence of myc contains at least
four detectable cis-acting regulatory elements, an upstream
positive element (E), two negative elements (NRE1 and
NRE2) and a cap-proximal 'core' promoter (see Figure 2),
which will all interact with trans-acting factors in the cell.
Eukaryote DNA may contain specific sequences which act as
targets for some of these trans-acting factors, and can titrate
these factors if supplied at sufficiently high concentrations.
There is evidence that this can occur in several systems and
also in the myc regulatory sequence (see following section).
At low carrier DNA concentrations the amount of target
sequence may be too low to titrate trans-acting factors, and
the effect of E balances the effects of NREs in LATK- cells.
As the concentration of carrier increases, specific sequences
in the DNA compete with the upstream E sequences for
trans-acting factors which modulate its activity, thus
unveiling the negative effects of the NRE sequences which
can then be detected by the terminal deletion. pUC18
plasmid DNA is unlikely to have specific target sites for
eukaryote transacting factors (except coincidentally) and
might be expected to have no significant effect on CAT
levels.
Further characterisation of NRE2
The magnitude of the negative effect of plasmids containing
NRE1 and NRE2 vary to some extent from experiment to
experiment (Whitelaw et al., 1988). We considered the
possibility that the cis-acting NREs interact with cellular
trans-acting factors present in limiting amounts. Increasing
concentrations of DNA containing myc promoter sequences
might then titrate out such factors leading to derepression of
unbound DNA molecules which remain.
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Figure 3 Cat activity of human c-myc/cat recombinant plasmids in mouse LATK- cells. Recombinants encompassing the entire
c-myc promoter domain (pB12) or the truncated promoter (position -290; p240) linked to cat are shown. Graphs show levels of
acetylated 14C chloramphenicol/5 x 1O' cells for 5 pg of recombinant plasmid pB 12 and the molar equivalent for p240 after
transfection into separate cultures using increasing amounts of carrier DNA. Each point represents the average of 2 values for
each experiment. Protocols for DNA transfections and CAT assays have been described previously (Whitelaw et al., 1988).
In order to test this we performed plasmid competition
assays in which the 5' sequences containing only hyper-
sensitive sites I, III and 112 (-2319 to -350; Figure 2) are
used as competitor in CAT assays where cat is driven by the
entire myc promoter region (plasmid pB12, Figure 3). As a
control the level of CAT activity obtained with the truncated
promoter (position -350) in which cat is driven by only the
core promoter containing hypersensitive sites 1111 and III2
(see Figures 1 & 2) was also measured. The results presented
in Figure 4 show that the competitor DNA can titrate out
factors responsible for repression of expression from pB12
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Figure 4 Competition assay for c-myc/cat recombinants. c-myc
sequences from -2319 to -350 alone were used in a
competition assay against pB 12 transfected into the same cells at
molar plasmid ratios of 1, 2, 5 and 10 competitor to parental
plasmid pB12. Results represent the CAT activity of l jug of a
promoterless cat construct (dotted line) and molar equivalents of
pB12 and pB14 (truncated deletion to position -350), expressed
as a percentage of pB14. Each point represents the average of 2
flasks for two separate experiments A and B.
and that levels of expression equal to or greater than that
obtained with cat driven by the truncated promoter can be
obtained.
Transcription factor binding sites in the regulatory domains
It is likely that the trans-acting factors which can be titrated
in the competition experiments are DNA-binding proteins
which affect the activity of the cis-acting regulatory DNA
sequences. These might be proteins which recognise and bind
to specific sequences, or proteins which interact through
protein-protein interactions. In order to begin analysis of the
regulatory domain, we examined the interaction of specific
DNA-binding proteins with NRE2 and the 'core' promoter
using partially and highly purified preparations of nuclear
proteins in in vivo DNAse 1 protection assays (Jones et al.,
1985). The results have been presented in detail elsewhere
(Whitelaw et al., 1988) but the footprints obtained using
partially purified nuclear extracts binding to NRE2 are
shown in Figure 2. Four distinct 'footprints' are obtained.
Using DNA-affinity purified preparations of transcription
factors Spl and CTF (CAAT Transcription Factor)
(Kadonaga & Tjian, 1985), it was possible to show that of
these one binding site was due to Spl and two adjacent
binding sites to CTF. Examination of the DNA sequence
confirms typical consensus signals for these DNA-binding
proteins. The fourth footprint encompasses the reported
location of hypersensitive site 112 (Siebenlist et al., 1984) and
although it contains an Spl-like sequence it bound neither
purified Spl nor CTF. This binding site may represent a
target for a so far unknown DNA-binding protein.
A summary of this study and a similar analysis of the
'core' promoter domain is included in Figure 2. This shows
the location and orientation of the DNA binding sites
relative to the other known features of the regulatory region.
We have not yet analysed NRE1 or E, or the NRE domains
suggested by the reports of Chung et al. (1986) or Hay et al.
(1987).
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Discussion
Cumulative experimental evidence to date suggests that
transcriptional control of the c-myc oncogene is particularly
complex. Despite efforts from a number of research groups,
the domains responsible for transcriptional regulation have
yet to be fully characterised. The emerging picture is one of
intricate interactions between multiple positive and negative
control elements. C-myc is expressed in many different cell
types. It appears to encode a protein(s) intimately involved
in the regulation of cell growth and differentiation and as
such may itself require to be regulated very precisely. It is
plausible that varying interactions occur between control
domains and trans-acting factors depending on the cell type
and stage of differentiation. That negative regulatory
elements identified by transient assays have in vivo signifi-
cance is suggested by the observations that such an element
detected in murine myc (which may correspond to our
NRE2) correlates with the position of chromosomal break-
points and proviral insertion sites in B- and T-cell neoplasia
(Remmers et al., 1986). Similarly mutations in the 3' region
of exon I in BL cells correlates with aberrant patterns of myc
transcription and may affect elongation block, or perhaps
the expression of MYC I (Cesarman et al., 1987; Hann et al.,
1988). Further efforts to identify the in vivo regulatory
function of these and the other elements described to date
are obviously crucial. It is also important to determine
whether alterations in the DNA sequence of the elements
themselves, or alteration in the trans-acting factors which
regulate their activity, are involved in the alteration of c-myc
expression associated with various types of cancer apart
from BL.
From the summary shown in Figure 2, we suggest a role
for specific DNA-binding proteins Spl and CTF in
modulating the activity of NRE2. Binding of these general
transcription factors have been associated so far with up-
regulation of promoter elements. If they are also involved in
negative regulation, the specificity of their effect on
transcription remains to be explained. Specificity could be
determined by the structure of the local DNA sequence
itself, by the orientation or spacing of binding or the nature
of other specific DNA binding proteins which interact with
the domain. Alternatively, specificity could be determined by
protein-protein interactions with other non-DNA binding
proteins, or a combination of all of these. Regulation of cis-
acting DNA sequences in transcription by the interaction of
acessory proteins with specific protein-DNA complexes has
been reported for other biological systems including the
interaction of herpes simplex virus with host cellular proteins
(Preston et al., 1988). Another possible mode of action of a
negative element might be to act as a promoter and lead to
'promoter occlusion effects' on downstream promoters as
previously suggested for bacteriophage lambda gene
expression (Adhya & Gottesman, 1982). In this regard, the
presence of an additional cap site (PO) has been reported
adjacent to NRE2 (Bentley & Groudine, 1986a).
It is obvious that the mechanisms by which expression of
the myc gene is regulated is both complex and little
understood at the present time. We are currently
investigating the role of Spl, CTF and the unknown protein
which binds at hypersensitive site 112, and the possible role
of accessory proteins, using a combination of site directed
mutagenesis, DNAse 1 protection studies, and analysis of
protein-DNA complexes.
We thank the Cancer Research Campaign of Great Britain for
support.
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